| Literature DB >> 32392783 |
Andrzej Kwiatkowski1, Tomasz Chludziński1, Tarik Saidi2,3, Tesfalem Geremariam Welearegay4,5, Aylen Lisset Jaimes-Mogollón6,7, Nezha El Bari3, Sebastian Borys8, Benachir Bouchikhi2, Janusz Smulko1, Radu Ionescu5.
Abstract
Here we present a proof-of-concept study showing the potential of a chemical gas sensors system to identify the patients with alveolar echinococcosis disease through exhaled breath analysis. The sensors system employed comprised an array of three commercial gas sensors and a custom gas sensor based on WO3 nanowires doped with gold nanoparticles, optimized for the measurement of common breath volatile organic compounds. The measurement setup was designed for the concomitant measurement of both sensors DC resistance and AC fluctuations during breath samples exposure. Discriminant Function Analysis classification models were built with features extracted from sensors responses, and the discrimination of alveolar echinococcosis was estimated through bootstrap validation. The commercial sensor that detects gases such as alkane derivatives and ethanol, associated with lipid peroxidation and intestinal gut flora, provided the best classification (63.4% success rate, 66.3% sensitivity and 54.6% specificity) when sensors' responses were individually analyzed, while the model built with the AC features extracted from the responses of the cross-reactive sensors array yielded 90.2% classification success rate, 93.6% sensitivity and 79.4% specificity. This result paves the way for the development of a noninvasive, easy to use, fast and inexpensive diagnostic test for alveolar echinococcosis diagnosis at an early stage, when curative treatment can be applied to the patients.Entities:
Keywords: AC fluctuation measurements; DC resistance measurements; breath analysis; chemical gas sensors; diagnosis; echinococcosis
Mesh:
Substances:
Year: 2020 PMID: 32392783 PMCID: PMC7249121 DOI: 10.3390/s20092666
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.576
Information about the volunteers included in the study.
| Patient no. | Disease 1 | Age | Gender 2 | Smoking Habit | Medication |
|---|---|---|---|---|---|
| 1 5 | AE | 69 | F | No | Sulfasalazine, Acidum, Folicum |
| 2 | Not AE | 36 | M | No | - |
| 3 5 | AE | 58 | M | No | Ramipril, Nebivolol, Propafenone |
| 4 4 | AE | 49 | M | Yes | Albendazole, Amlodipine, Bisoprolol |
| 5 4 | AE | 74 | F | No | Enalapril, Amlodipine |
| 6 5 | AE | 73 | F | No | Albendazole, Indapamide, Ramipril, Bisoprolol |
| 7 | Not AE | 30 | F | No | - |
| 8 4 | AE | 61 | F | Yes | Albendazole, Furosemide, Spironolactone, Propranolol |
| 9 | Not AE | 50 | F | No | - |
| 10 5 | AE | 54 | F | No | Albendazole, Bisoprolol, Perindopril |
| 11 4 | AE | 60 | F | No | Albendazole, Furosemide, Spironolactone |
| 12 5 | AE | 75 | F | No | Albendazole, Valsartan, Metformin |
| 13 | Not AE | 46 | F | No | Ramipril |
| 14 | Not AE | 44 | F | No | - |
| 15 5 | AE | 35 | F | No | Albendazole |
| 16 3,5 | AE after liver transplantation | 59 | F | No | Albendazole, Tacrolimus, Calcium |
| 17 | None | 37 | M | No | - |
1 AE = alveolar echinococcosis. 2 M = male; F= female. 3 This patient had recurrence of AE in transplant liver. She had specific changes in CT and still positive serological tests. 4 Confirmed case of AE according to Brunetti’s criteria [17]. 5 Probable case of AE according to Brunetti’s criteria [17].
Figure 1(a) Measurement setup; (b) Insight of the AC fluctuations measurement board.
Figure 2Electronic circuit.
Figure 3Measurement setup during breath sample injection.
Figure 4DC sensors responses in the presence of: (a) Breath sample of a patient with confirmed echinococcosis; (b) Breath sample of a control volunteer; (c) Room air. (d–f): Zoom of the AuWO3 sensor responses presented in Figure 4a–c, respectively. AE: Alveolar echinococcosis; Not AE: Control.
Figure 5Power spectral densities of voltage fluctuations measured across the sensors exposed to a breath sample, as well as before sample measurement and after cleaning the test chamber with synthetic air. (a) AuWO3 sensor; (b) MiCS 6814#NH3 sensor.
Figure 6Average power spectral densities (PSD) value of sensors fluctuations recorded in the presence of: (a) Breath samples of all AE patients; (b) Breath samples of all control volunteers; (c) All room air samples. AE: Alveolar echinococcosis; Not AE: Control.
Discrimination between the AE patients and controls (mean values (%) ± standard deviation)
| Sensors | Features | Classification Success Rate | Sensitivity | Specificity | |
|---|---|---|---|---|---|
| Individual sensors | S1 | F1,F5,F6 | 49.1 ± 20.2% | 58.7 ± 29.5% | 31.2 ± 36.8% |
| S2 | F4,F6 | 49.7 ± 20.3% | 57.8 ± 30.7% | 34.5 ± 37.3% | |
| S3 | F5,F6 | 63.4 ± 20.0% | 66.3 ± 27.6% | 54.6 ± 41.9% | |
| S4 | F3,F6 | 45.6 ± 21.8% | 49.2 ± 30.9% | 37.4 ± 37.4% | |
| Sensors array | DC | S1: F1,F3 | 73.4 ± 19.3% | 75.9 ± 24.5% | |
| 64.2 ± 39.6% | |||||
| AC | S1: F1,F4 | 90.2 ± 16.4% | 93.6 ± 16.8% | 79.4 ± 35.8% | |
Figure 7Discriminant Function Analysis (DFA) models built with all samples (without bootstrap validation), shown for visualization purpose only: (a) DFA model built with features extracted from the DC measurements; (b) DFA model built with features extracted from the AC measurements. The features used to build the DFA models are indicated in Table 2. AE: Alveolar echinococcosis; Not AE: Control. CV1: First (and most discriminative) canonical variable of the DFA model; CV2: Second canonical variable of the DFA model. The decision border is given by the vertical dashed line passing through the zero value on the CV1 axis.